EBS

Emergent Biosolutions, Inc.

8.05

USD

EBS Earnings Reports

Positive Surprise Ratio

EBS beat 21 of 41 last estimates.

51%

Next Report

Date of Next Report

May 05, 2026

Estimate for Q1 26 (Revenue/ EPS)

$162.10M

-$0.25

Implied change from Q4 25 (Revenue/ EPS)

+9.01%

-41.86%

Implied change from Q1 25 (Revenue/ EPS)

-27.05%

-135.21%

Emergent Biosolutions, Inc. earnings per share and revenue

On Feb 26, 2026, EBS reported earnings of -0.43 USD per share (EPS) for Q4 25, missing the estimate of 0.11 USD, resulting in a -487.04% surprise. Revenue reached 148.70 million, compared to an expected 219.68 million, with a -32.31% difference. The market reacted with a -26.58% price change (close before vs. close after earnings).

Looking ahead to Q1 26, -- analysts forecast an EPS of -0.25 USD, with revenue projected to reach 162.10 million USD, implying an decrease of -41.86% EPS, and increase of 9.01% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Acumen Pharmaceuticals, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.41

Surprise

+11.29%

Spero Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.20

Actual

$0.53

Surprise

+359.80%

Rani Therapeutics Holdings, Inc. Class A Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-2.94%

Alpha Cognition Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.30

Surprise

-8.93%

Cognition Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.02

Surprise

+76.47%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

Actual

-$0.71

Surprise

CollPlant Biotechnologies Ltd Ordinary Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.67

Surprise

-245.72%

FAQ

What were Emergent Biosolutions, Inc.'s earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Emergent Biosolutions, Inc. reported EPS of -$0.43, missing estimates by -487.04%, and revenue of $148.70M, -32.31% below expectations.

How did the market react to Emergent Biosolutions, Inc.'s Q4 2025 earnings?

The stock price moved down -26.58%, changed from $11.10 before the earnings release to $8.15 the day after.

When is Emergent Biosolutions, Inc. expected to report next?

The next earning report is scheduled for May 05, 2026.

What are the forecasts for Emergent Biosolutions, Inc.'s next earnings report?

Based on -- analysts, Emergent Biosolutions, Inc. is expected to report EPS of -$0.25 and revenue of $162.10M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.